<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01968460</url>
  </required_header>
  <id_info>
    <org_study_id>P2B001/001</org_study_id>
    <nct_id>NCT01968460</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease</brief_title>
  <official_title>A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharma Two B Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharma Two B Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate an oral fixed-dose, once daily product that combines pramipexole and
      rasagiline for the treatment of early Parkinson's disease.

      Animal studies support the therapeutic advantage of combining low doses of rasagiline and
      pramipexole and suggest further improvement when both are administered in a sustained
      fashion. Both rasagiline and pramipexole are well known marketed drugs for Parkinson's
      disease with a good safety profile. combining the drugs in low doses and controlled release
      may provide better symptom management than the existing drugs alone or together.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total UPDRS I, II, III scores</measure>
    <time_frame>Week 12</time_frame>
    <description>Change from baseline to final visit (week 12) in total UPDRS score (defined as sum of parts I, II and III, scores (0-176).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UPDRS ADL (part II)</measure>
    <time_frame>Week 12</time_frame>
    <description>Change from baseline in individual UPDRS ADL (part II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-S</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in individual Clinical Global Impression - Severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Motor (part III)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in individual UPDRS motor (part III)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDQ39</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in individual Parkinson's Disease Questionnaire - 39</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>P2B001 Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P2B001 Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),</intervention_name>
    <description>Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily</description>
    <arm_group_label>P2B001 Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),</intervention_name>
    <description>Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily</description>
    <arm_group_label>P2B001 Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female ≥35 years of age to ≤75 years of age at the time of
             enrollment.

          -  Subject has idiopathic Parkinson's disease consistent with the UK Brain Bank Criteria;
             must have bradykinesia with sequence effect and rest tremor or prominent motor
             asymmetry.

          -  Subject with disease duration no longer than 3 years and 0 months.

          -  Subject has a Hoehn &amp; Yahr (H&amp;Y) stage score of &lt; 3.

          -  Subject has a MMSE score ≥ 26

        Exclusion Criteria:

          -  Subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to
             drugs, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or
             degenerative disease).

          -  Subject has a history of psychosis or hallucinations within the previous 12 months.

          -  Subject who is taking anticholinergic drugs.

          -  Subject has previous exposure to levodopa or a dopamine agonist for longer than 4
             weeks; if previous exposure was less than 4 weeks then it must not be within 2 months
             prior to the baseline visit.

          -  Subject has previous exposure to a MAO-B inhibitor for longer than 4 weeks; if
             previous exposure was less than 4 weeks then it must not be within 3 months prior to
             the baseline visit.

          -  Subject who is taking MAO inhibitors, potent CYP1A2 inhibitors, e,g, Ciprofloxacin,
             Dextromethorphan or antitussive agent, analgesic agents such as tramadol, meperidine,
             methadone and propoxyphene, strong 3A4 inducers, e.g., St. John's Wort or
             cyclobenzaprine (tricyclic muscle relaxant), dopamine antagonists, such as the
             neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide.
             Probenecid, cimetidine, ranitidine, diltiazem, verapamil and quinidine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>pninit litman, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Pharma Two B Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>P2B001 Site Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Manchester</name>
      <address>
        <city>Manchester</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Port Charlotte</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Augusta</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 site Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site west Bloomfield</name>
      <address>
        <city>West Bloomfield Township</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Golden Valley</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Camden</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site New Brunswick</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 site Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Durham</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Tulsa</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Roanoke</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Asaf Harofe</name>
      <address>
        <city>Beer Yakov</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Rambam Israel</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Belinson</name>
      <address>
        <city>Pethch Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Site Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2013</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease, Rasagiline, Pramipexole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

